# Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis

> **NCT07440654** · NA · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 40 (estimated)

## Conditions studied

- aGVHD Prophylaxis

## Interventions

- **DRUG:** Gecacitinib

## Key facts

- **NCT ID:** NCT07440654
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2029-09-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07440654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07440654, "Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07440654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*